1. Home
  2. GF vs NYXH Comparison

GF vs NYXH Comparison

Compare GF & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GF

New Germany Fund Inc. (The)

HOLD

Current Price

$11.50

Market Cap

184.9M

Sector

Finance

ML Signal

HOLD

Logo Nyxoah SA

NYXH

Nyxoah SA

HOLD

Current Price

$4.64

Market Cap

188.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GF
NYXH
Founded
1990
2009
Country
Germany
Belgium
Employees
N/A
N/A
Industry
Investment Managers
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
184.9M
188.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
GF
NYXH
Price
$11.50
$4.64
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$12.67
AVG Volume (30 Days)
28.1K
27.6K
Earning Date
01-01-0001
11-13-2025
Dividend Yield
0.82%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$6,616,215.00
Revenue This Year
N/A
$75.27
Revenue Next Year
N/A
$277.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
10.96
52 Week Low
$7.38
$4.35
52 Week High
$9.41
$11.87

Technical Indicators

Market Signals
Indicator
GF
NYXH
Relative Strength Index (RSI) 61.97 43.28
Support Level $11.28 $4.47
Resistance Level $11.54 $4.86
Average True Range (ATR) 0.17 0.19
MACD 0.01 -0.00
Stochastic Oscillator 91.84 18.21

Price Performance

Historical Comparison
GF
NYXH

About GF New Germany Fund Inc. (The)

NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: